Windy with rain and snow showers this evening transitioning to snow showers overnight. Low 32F. Winds WSW at 20 to 30 mph. Chance of precip 50%. Winds could occasionally gust over 40 mph..
Windy with rain and snow showers this evening transitioning to snow showers overnight. Low 32F. Winds WSW at 20 to 30 mph. Chance of precip 50%. Winds could occasionally gust over 40 mph.
Updated: January 19, 2023 @ 6:10 pm
Horizon Therapeutics (NQ: HZNP )
99.77 -0.03 (-0.03%) Streaming Delayed Price Updated: 2:18 PM EDT, Jun 7, 2023 Add to My Watchlist
Headline News about Horizon Therapeutics
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
May 30, 2022
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for...
According to Benzinga Pro, during Q1, Horizon Therapeutics (NASDAQ:HZNP) earned $204.26 million, a 17.95% increase from the preceding quarter. Horizon Therapeutics's sales decreased to $885.25 million,...
Horizon Therapeutics Begins Patient Enrolment in Phase 2 trial of Daxdilimab (HZN-7734) for Alopecia Areata
May 17, 2022
Horizon Therapeutics plc (NASDAQ: HZNP) enrolled first patient in a Phase 2, open-label, proof-of-concept trial of its drug candidate Daxdilimab (HZN-7734) to treat people with moderate-to-severe...
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following